05-Nov-2026 13:23:24
SHILPA MEDICARE Q2 FY27: RECORD REVENUE UP 45% YOY, EBITDA JUMPS 37%; API BUSINESS HITS ALL-TIME HIGH, ORION BIOSIMILAR PARTNERSHIP EXPANDS & STRONGER FY27 OUTLOOK
• Revenue: Grew approximately 45% YoY, reaching an all-time quarterly high. • EBITDA: Increased approximately 37% YoY to a record level, with margins at 28%. • API Business: Achieved highest-ever quarterly revenue, supported by strong performance across all three business verticals. • Novel FDF Portfolio: Multiple niche product launches planned through FY27 and beyond, expected to support future growth. • Orion Partnership: Expanded collaboration with Orion Corporation for exclusive European rights to Nivolumab biosimilar in immuno-oncology. • Biosimilar Expansion: Shilpa will act as development and supply partner, strengthening its complex therapies portfolio. • Capital Efficiency: ROCE continues to improve, reflecting better capital utilisation. • ESG Performance: CRISIL ESG score improved, reflecting progress in sustainability and governance. • Management Outlook: Expects a stronger FY27, supported by robust H1 momentum, new product launches, expanding global partnerships and a maturing innovation pipeline.
SHILPA MEDICARE LTD